To receive the Femtech World newsletter, sign up here.
News
US maternity clinic raises a US$28m to expand nationally
Oula plans to expand its hybrid care approach and launch new services for those in their reproductive years
The US maternity care clinic Oula has raised a US$28m in funding to introduce new services and expand nationally.
Oula aims to brings together the best of midwifery and obstetrics to deliver, what the start-up describes as, “whole-person” care.
Since its launch in 2021, the clinic, which can currently be found in three locations in New York City, has focused on providing a better care experience for women, combing modern medicine with a more personalised approach.
Now, with nearly US$50m in total funding, Oula plans to expand its hybrid care approach to more markets beyond New York City and launch new services for those in their reproductive years.
“The power of Oula’s collaborative approach to care is that patients feel seen and heard during a transformative moment in their lives, health systems are able to address the evolving expectations of their communities and we can move the needle on unacceptable outcomes and disparities in maternal care,” explained Adrianne Nickerson, co-founder and CEO and of Oula.
Elaine Purcell, co-founder and COO of Oula, said: “We’ve not only proven that this model works, but that it’s what patients from all backgrounds, birth preferences, and income levels are looking for.
“Whether you can afford concierge care or are on Medicaid, we are building a modern and compassionate pregnancy care model that delivers better outcomes than the system has proven to do. We deserve better and yes, you can have it all.”
Clara Sieg, partner and founding member at Revolution Ventures, which co-led the funding round alongside Maverick Ventures, said: “Pregnancy outcomes in the US have consistently deteriorated over the past two decades.
“Oula is solving this mounting crisis by reimagining the maternal experience with midwifery-first, team-based care supported by virtual wrap-around services and a tech-enabled platform.
“We are excited to partner with the team as Oula scales its care model and empowers women to receive personalised, trusted support throughout pregnancy.”
David Singer of Maverick Ventures, added: “We are thrilled to back a company that effectively aligns the needs of mothers, health systems and payers, and breaks the false binary between unmedicalised and hypermedicalised care.”
Instead of waiting for the standard eight-week ultrasound, Oula allows patients to book an appointment as soon as their positive pregnancy test, supporting patients in the postpartum period.
The clinic also plans to introduce pre-conception coaching visits and expanded miscarriage support options in the coming year.
Joanne Schneider, Oula’s chief experience officer, said: “Oula is distinct in the pregnancy landscape today not only in redesigning the standard pregnancy and birth experience, but also in filling the gaps where the medical system typically fails patients: early pregnancy care and postpartum. Even when there aren’t any medical needs, these are times when people need emotional support.
She added: “Miscarriages are extremely common, so I was shocked at how isolated I felt when I had my own miscarriage. It’s not considered a big deal medically, but it’s a very big deal when you are going through it.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Fertility4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment